Psilocybin is the classic psychedelic with the strongest trial evidence in psychiatry, studied under close supervision for depression and for the distress of a life-threatening illness. In the largest controlled trial, a single 25 mg dose given with psychological support eased treatment-resistant depression by 6.6 points more than a tiny comparison dose at three weeks on a 0 to 60 scale, and that gain had faded by twelve weeks. Tested head-to-head against a standard antidepressant, it did not clearly beat the drug on the main measure. In people facing a life-threatening cancer, a single session with support eased depression and anxiety, and most were still improved around six months later.
One limit runs through all of it: these drugs produce effects so noticeable that participants and raters guess who got the drug more than 90 percent of the time, so the measured benefit is likely inflated. This page is education about the research, the law, and the risks. It is not a guide to using psilocybin, and it carries no dosing and no sourcing.
Findings & Outcomes
What It Is
Psilocybin is the compound in the mushrooms sometimes called magic mushrooms. The body converts it to psilocin, which acts on the serotonin system and produces a temporary, dose-dependent change in perception, mood, and sense of self that lasts a few hours. In research it is the most studied of the classic psychedelics, ahead of LSD and DMT, and the trial evidence is strongest for two uses: depression, including depression that has not responded to standard treatment, and the depression and anxiety that come with a life-threatening illness.
In every trial that produced these results, the setting was the same: a screened patient, a prepared session with trained support present, and structured follow-up afterward. That setting is part of the treatment, and it is a different situation from taking a substance alone. This page is education about what the research shows, where the law stands, and what the risks are. It carries no dosing and no sourcing.
What It Does
The findings are graded claim by claim in the research section below. The largest controlled trial to date gave a single 25 mg dose with psychological support to people whose depression had not responded to standard treatment. Depression scores fell 6.6 points more than in a group given a 1 mg comparison dose at three weeks, measured on the MADRS scale, which runs from 0 to 60. A 10 mg dose did not separate from the comparison. The three-week gain had faded by twelve weeks, and side effects such as headache, nausea, and low mood were common.
A separate trial tested psilocybin directly against escitalopram, a standard antidepressant. On the main depression measure at six weeks the two did not differ by a significant margin: the gap was 2.0 points on the QIDS-SR-16, with a confidence interval that crossed zero. Some secondary measures leaned toward psilocybin, but the trial was not large enough to settle them. The result that gets repeated, that psilocybin outperformed an antidepressant, is not what the primary outcome showed.
In people facing a life-threatening cancer, the evidence is more consistent. Two randomized crossover trials each gave a single moderate-to-high dose with psychological support, and both produced immediate, large reductions in depression and anxiety alongside a greater sense of meaning. About 60 to 80 percent of participants still showed a meaningful improvement roughly six months later. Both trials were small, and in a crossover design most people could tell which session was active.
One limit weighs on all of it. Psilocybin produces unmistakable effects, so in a trial almost everyone can tell whether they received the drug or the placebo. A systematic review found this functional unblinding is pervasive, with participants and raters in psilocybin studies correctly identifying who got the drug more than 90 percent of the time. When people know they received a treatment they hoped would work, expectation can lift their scores, and that expectation is very difficult to separate from the drug. This does not mean the benefit is absent.
It means the measured size of the benefit is likely inflated, and the true size of the drug effect is not yet established.
That is the accurate reading. For decades the received view held that psilocybin was a dangerous drug of no medical value, a stance set in law in the early 1970s, and the trial evidence no longer supports it. As attention grew, a second belief took hold, that it is close to a cure. The data sit between the two: a real and repeatable short-term signal in depression and in end-of-life distress, measured through trials whose blinding is weak enough that the size of the effect stays uncertain.
The Research & Studies
Everything here is based on the research we have collected and checked, sorted into groups and ordered with the strongest evidence first. Click any claim to open the studies behind it.
Mood & stress
One 25 mg psilocybin dose eased treatment-resistant depression 6.6 points more than a low dose at three weeks
A single high dose of psilocybin, given with therapy, eased treatment-resistant depression more than a tiny comparison dose after three weeks. The improvement had faded by twelve weeks, and side effects were common.
The phase 2b COMP360 trial (Goodwin et al., NEJM 2022) randomized 233 adults with treatment-resistant depression to a single 25 mg, 10 mg, or 1 mg dose of synthetic psilocybin with psychological support. On the MADRS scale (0 to 60), the 25 mg group improved 6.6 points more than the 1 mg comparator at week 3, while the 10 mg group did not separate from it. The between-group difference was no longer statistically significant at week 12. Adverse events, including headache, nausea, and low mood, occurred in most participants, and suicidal ideation and self-injurious behavior were reported across dose groups.
The study · 1
Goodwin et al., single-dose psilocybin for a treatment-resistant episode of major depression · N Engl J Med 2022;387:1637-1648
Psilocybin did not clearly beat a standard antidepressant on the main depression measure at six weeks
When psilocybin was tested head-to-head against a standard antidepressant, the two came out about even on the main measure of depression. Some secondary measures leaned toward psilocybin, but the study was too small to decide.
Carhart-Harris et al. (NEJM 2021) randomized 59 adults with moderate-to-severe depression to two doses of psilocybin with support, or to six weeks of daily escitalopram plus two very low psilocybin doses. On the primary outcome, the change in QIDS-SR-16 score at six weeks, the between-group difference was -2.0 points favoring psilocybin (95% CI -5.0 to 0.9, P=0.17), which was not statistically significant. Several secondary outcomes favored psilocybin, but the trial was not designed or powered to confirm them.
The study · 1
Carhart-Harris et al., trial of psilocybin versus escitalopram for depression · N Engl J Med 2021;384:1402-1411
A single psilocybin session eased cancer-related distress, with 60 to 80% still improved at about six months
For people facing life-threatening cancer, a single psilocybin session with support eased depression and anxiety, and most were still better roughly six months later.
A Johns Hopkins crossover trial (Griffiths et al. 2016, 51 patients) and an NYU crossover trial (Ross et al. 2016, 29 patients) each gave people with cancer-related depression and anxiety a single moderate-to-high psilocybin dose with psychological support, compared with a very low dose or an active control. Both produced immediate, substantial, and sustained decreases in depressed mood and anxiety alongside increases in quality of life and sense of meaning; at roughly six months, 60 to 80% of participants still showed clinically significant improvement.
The studies · 2
Griffiths et al., psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer · J Psychopharmacol 2016;30:1181-1197
Ross et al., rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer · J Psychopharmacol 2016;30:1165-1180
Evidence And Methods
Participants and raters correctly guess who got psilocybin more than 90% of the time, so the benefit is hard to separate from expectation
Because psilocybin produces obvious effects, people in the studies can usually tell whether they got the active drug, which makes the benefit hard to separate from expectation.
A systematic review of blinding integrity in psychedelic randomized trials (Orsini et al. 2026) found that only a minority of trials assessed blinding at all, while more than half named it as a limitation. Where it was measured, functional unblinding was substantial: psilocybin studies frequently reported that both participants and raters correctly guessed allocation above 90 percent. This does not show the treatments lack effect; it shows the measured effect size cannot be firmly attributed to the drug while blinding stays this weak.
The study · 1
Orsini et al., blinding integrity in psychedelic randomized clinical trials, a systematic review · JAMA Psychiatry 2026
How it works
Psilocybin acts through its metabolite psilocin on the 5-HT2A serotonin receptor
The body turns psilocybin into psilocin, which switches on one serotonin receptor (5-HT2A). That single receptor drives the experience, and it is thought to loosen fixed patterns of thought.
Comprehensive pharmacology reviews (Nichols 2016) establish that the subjective effects of classic psychedelics depend on agonism at the serotonin 5-HT2A receptor: blocking that receptor blocks the experience. Psilocybin itself is largely inactive and is dephosphorylated to psilocin, the active agonist. Activation is thought to increase the flexibility of cortical activity and reduce the grip of rigid, self-referential thinking, a mechanism of interest for depression and end-of-life distress.
The study · 1
Nichols et al., psychedelics, a comprehensive pharmacology review · Pharmacol Rev 2016;68:264-355
How It Works
The effects of psilocybin depend on one main mechanism. The body converts it to psilocin, which activates the serotonin 5-HT2A receptor. Blocking that single receptor blocks the experience, which is how researchers know it is central. Activating it appears to increase the flexibility of activity across the cortex and to loosen the fixed, self-referential thinking that runs through depression and rumination. The idea behind the therapy is that a person, well supported, can revisit thoughts, memories, and feelings from a different vantage point, and that the shift can outlast the few hours the drug is active.
What Happens During and After a Session
1The receptor and the acute effect
Psilocin switches on the serotonin 5-HT2A receptor across the cortex. Over the following minutes to hours this changes perception, emotion, and the sense of self. In the studied setting the person is prepared, supported by trained staff, and in a calm room, because the survey evidence shows difficulty and risk rise at higher doses and when support is absent.
2The days after
The subjective experience ends within hours, but many trials report a change in mood that appears over the following days. In treatment-resistant depression this early separation from the comparison dose was clear at three weeks. The mechanism proposed for a lasting shift, a temporary window of greater mental flexibility, is still being worked out, and mechanism alone does not establish clinical benefit.
3Weeks to months
The depression signal in the largest trial had faded by twelve weeks, which is why the compound is studied with structured follow-up rather than as a single event. In the cancer trials the benefit held longer, with most people still improved around six months. How durable the effect is, and for whom, is one of the open questions the research has not settled.
The Legal Position
The law and the science are not in the same place. In the United States:
- Psilocybin is Schedule I federally, the most restricted category, so outside an authorized research or approved-treatment setting its use is illegal.
- Oregon and Colorado have created state-regulated frameworks for supervised adult psilocybin use, legal under state law but not under the federal classification.
- It has not been approved by the FDA for any condition, so it is not something a doctor can prescribe.
Elsewhere it remains investigational, reachable only inside clinical trials and expanded-access programs. None of this page is a route to obtaining psilocybin; it is a description of where the law currently stands.
Go Deeper
- Psychedelics in mental health: the wider picture, where psilocybin sits beside MDMA-assisted therapy for PTSD, the approved relative esketamine, the 2024 FDA decision, and the blinding problem that runs across the whole field.
- Depression: what actually helps: the full range of treatments for depression, and where an investigational option like psilocybin sits among the ones with a longer track record.
- Anxiety: the condition that runs alongside much of this research, and the treatments with the strongest evidence behind them.
The Chinese Medicine View
Chinese medicine has a long-standing frame for altered states of mind, and it leans toward caution. The Heart is said to house the Shen, the spirit or consciousness, and clear thought, steady emotion, and restful sleep are read as signs of a settled Shen. A mind flooded, disoriented, or thrown into fear or agitation is described as a disturbance of the Shen, and the classical tradition treats such disturbance as something to calm and anchor. The bias of the medicine is toward grounding: settling the Shen, harmonizing the Heart and Liver, and rooting a scattered mind back in the body through stillness, breath, and regular life.
Read through that lens, an intense, mind-altering experience is not neutral. It could be seen as deliberately stirring the Shen, which the tradition would approach with great care, especially in someone already depleted, agitated, or unsettled, and especially without skilled support and a calm setting. This is an interpretation, not a verdict, and not a claim that the tradition anticipated modern trials. It lines up, in its own language, with what the clinical evidence keeps showing: that preparation, support, and a stable state shape the outcome, and that a fragile person is the one most likely to be harmed. The wider preventive tradition of Yang Sheng, nourishing life, would place the emphasis on grounding practices first.
Cautions For This Practice
Everything to be aware of is here, in one place. This practice suits most healthy people; a few situations call for real care.
Psychedelics triggered mania in 5.8% to 30% of people and can provoke psychosis in the vulnerable
The meta-analysis (Eskinazi et al. 2026) pooled controlled trials and naturalistic studies. Rates of hypomania or mania ran from 5.8% in controlled psilocybin-assisted therapy trials for depression up to 30% in naturalistic use among people with bipolar spectrum conditions. A separate narrative review of psychedelics and schizophrenia spectrum disorders (Brar et al. 2026) concludes they may trigger psychosis in vulnerable individuals, while noting the magnitude of that risk is inadequately quantified. This is why trials screen out a personal or family history of bipolar disorder or psychosis.Eskinazi et al., psychedelic-induced hypomania and mania, a systematic review and meta-analysisBrar et al., the intersection between psychedelics and schizophrenia spectrum disorders, reevaluating risk and therapeutic potential
In unsupervised use, 11% recalling a difficult experience put themselves or others at risk of physical harm
An online survey (Carbonaro et al. 2016) asked people (78% male, mean age around 30) about the single most psychologically difficult experience of their life with psilocybin mushrooms. Eleven percent reported putting themselves or others at risk of physical harm, 2.6% behaved aggressively, and 2.7% sought medical help; of those whose experience was more than a year earlier, 7.6% had sought treatment for enduring symptoms. Difficulty, dose, and the absence of physical comfort and social support all raised the likelihood of risk. Despite the difficulty, 84% still reported benefiting from the experience overall.Carbonaro et al., survey study of challenging experiences after ingesting psilocybin mushrooms
Mixing a classic psychedelic with lithium brought on seizures in 47% of reported cases
Researchers (Nayak et al. 2021) analyzed self-reported online accounts of combining a classic psychedelic with a mood stabilizer. Of 62 lithium-plus-psychedelic reports, 47% involved seizures, an additional 18% involved a bad trip, and 39% involved a need for medical attention; of 34 lamotrigine-plus-psychedelic reports, none involved seizures. The authors conclude the combination may pose a significant seizure risk for people taking lithium.Nayak et al., classic psychedelic coadministration with lithium, but not lamotrigine, is associated with seizures
This is not a guide to using psilocybin
This page is education about the research, the law, and the risks. It carries no dosing, no sourcing, and no instructions for use. Use outside an approved-treatment or research setting is illegal in most places, and unsupervised use carries psychological and medical risk. The trial results come from screened patients in prepared sessions with trained support, which is a very different situation from taking a substance alone.
Bipolar disorder and a history of psychosis
A personal or family history of bipolar disorder or of psychosis is the most important reason for caution. A meta-analysis found rates of psychedelic-linked hypomania or mania ranging from about 5.8% in controlled psilocybin depression trials to 30% in naturalistic use by people with bipolar spectrum conditions, and reviews note that psychedelics can provoke psychosis in vulnerable people. This is why trials screen these histories out.
Serotonergic medicines and lithium
Serotonin-based antidepressants (SSRIs and SNRIs) can blunt the effect of psilocybin, and combining serotonergic drugs raises the concern of too much serotonin. Combining a classic psychedelic with lithium has been linked to seizures in a large share of reported cases. Anyone on psychiatric medication is in a situation where these interactions can be dangerous, and a prescribing clinician is the right person to consult before any change.
Set, setting, and supervision
The research points repeatedly to the same thing: preparation, a calm and safe environment, and skilled support shape how an experience goes. In the survey evidence, difficulty and the risk of harm rose at higher doses and when support and physical comfort were absent. The phrase the field uses is set, setting, and supervision, and it separates the studied conditions from unsupervised use.
Psilocybin is the most studied classic psychedelic and shows a real short-term signal in depression and end-of-life distress, and it is a potent drug whose risks depend heavily on the person, the dose, and the setting. The stance here is to inform: read the evidence at its true strength, take the risks seriously, and, for anything touching your own care or medication, talk it through with a qualified clinician.
Common Questions
Does psilocybin work for depression?
There is a real short-term signal, measured in trials that have a clear limit. In the largest controlled trial, a single 25 mg dose with psychological support eased treatment-resistant depression by 6.6 points more than a 1 mg comparison dose at three weeks on the 0 to 60 MADRS scale, and that gain had faded by twelve weeks. Tested head-to-head against the antidepressant escitalopram, it did not clearly beat the drug on the main measure. The benefit is promising and early, not settled.
Can I get psilocybin as a treatment?
Not as an approved treatment. The FDA has not approved psilocybin for any condition, so a doctor cannot prescribe it. It is Schedule I federally, which makes its use illegal outside an authorized research or approved-treatment setting. Oregon and Colorado have state-regulated frameworks for supervised adult use, legal under state law but not under federal law. If standard treatments have not worked for you, the productive step is a conversation with a mental-health clinician about the options that do exist, including trials you may be eligible for.
Why is the evidence described as uncertain if the trials were positive?
Because psilocybin produces obvious effects, so almost everyone in a trial can tell whether they got the drug or the placebo. A systematic review found participants and raters guessed correctly more than 90 percent of the time. When people know they received a treatment they hoped would help, expectation can raise their scores, and that expectation is very hard to separate from the drug. The benefit is not absent; its measured size is likely inflated, and the true effect is not yet established.
Who should be especially careful?
The risks fall hardest on specific people, which is why trials screen for them. A personal or family history of bipolar disorder or of psychosis is the most important, because psilocybin can trigger mania or, in vulnerable people, psychosis. Anyone taking lithium is in interaction territory linked to seizures, and serotonin-based antidepressants both blunt the effect and raise interaction concerns. A person who is currently very unsettled or unsupported is the one the evidence suggests is most likely to have a difficult experience.
Explore Related
Other pages this one connects to, by the evidence they share, the outcomes they touch, and the ground they cover.
All 10 sources on this page independently checked and cross-referenced.
Thomas Dehli, Founder & Editor, Sacred Lotus
Sacred Lotus has published Chinese medicine reference material since 2001. Integrative pages are held to the same standard as the herb and formula library: cite the source, grade the claim at its real strength, and say where the research has not looked. This page is educational and it is not medical advice. Last reviewed and updated August 10, 2026.
Evidence strength
How confidently the research supports a claim. Strength describes the evidence, not our endorsement.